Myelodysplastic Syndrome (MDS)

4 protocols meet the specified criteria

OCR13125

A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic Syndrome (BMT CTN #1102)

OCR13968

A phase I clinical trial to evaluate the maximally tolerated dose (MTD), dose limiting toxicities (DLTs) and safety profiles of increasing doses of lenalidomide after allo-HCT in AML and MDS subjects with minimal residual disease (MRD) detected by the CD34+ mixed chimerism analysis

OCR14447

A Phase 1b Dose Escalation Study of OXi4503 as a Single Agent and in Combination with Cytarabine with Subsequent Combination Phase 2 Cohorts for Subjects with Relapsed/Refractory Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS)

OCR14834

A Phase III, International, Randomized, Controlled Study of Rigosertib versus Physicians Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent